This HTML5 document contains 34 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n9http://linked.opendata.cz/resource/drugbank/drug/DB06366/identifier/kegg-drug/
n20http://linked.opendata.cz/resource/drugbank/dosage/
n8http://linked.opendata.cz/resource/drugbank/drug/DB06366/identifier/drugbank/
n11http://www.drugs.com/
n4http://linked.opendata.cz/resource/drugbank/drug/DB06366/identifier/national-drug-code-directory/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/patent/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n7http://linked.opendata.cz/ontology/drugbank/
n16http://linked.opendata.cz/resource/drugbank/property/
n5http://linked.opendata.cz/resource/drugbank/drug/DB06366/identifier/wikipedia/
n19file:/data/uv/backend/working/exec_7200/storage/dpu_9769/1/www.rxlist.com/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06366
rdf:type
n7:Drug
n7:description
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. FDA approved June 8, 2012.
n7:dosage
n20:271B4C5D-363D-11E5-9242-09173F13E4C5 n20:271B4C5E-363D-11E5-9242-09173F13E4C5
n7:generalReferences
# Protein sequence "Link":www.freepatentsonline.com/20110117097.pdf # FDA label
n7:group
approved
n7:halfLife
18 days
n7:indication
Pertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
owl:sameAs
n15:DB06366
dcterms:title
Pertuzumab
adms:identifier
n4:50242-145-01 n5:Pertuzumab n8:DB06366 n9:D05446
n7:mechanismOfAction
Pertuzumab is a humanized monoclonal antibody designed to bind to the HER2 receptor and inhibit the ability of HER2 to interact with other HER family members (HER1, HER2, HER3, and HER4) on the surface of cancer cells. The HER signaling pathway plays a role in the formation and growth of numerous cancers, and previous clinical trials of pertuzumab in a single agent setting had suggested clinical activity - including stable disease - in heavily pretreated patients with advanced ovarian and breast cancers.
n7:patent
n18:2579861 n18:2376596
n7:synonym
2C4 Antibody Omnitarg MOAB 2C4 Monoclonal Antibody 2C4 rhuMAb-2C4
n7:toxicity
The most common adverse reactions (> 30%) with PERJETA in combination with trastuzumab and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy.
n7:volumeOfDistribution
5.12 L
n12:hasAHFSCode
n17:10-00
foaf:page
n11:perjeta.html n19:perjeta-drug.htm
n7:Molecular-Weight
n16:271B4C5F-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n13:L01XC13
n7:absorption
When an initial dose of 840 mg followed by a maintenance dose of 420 mg every three weeks thereafter is administered, steady-state concentrations were achieved on the first maintenance dose.
n7:affectedOrganism
Humans and other mammals
n7:casRegistryNumber
380610-27-5
n7:category
n7:clearance
0.24 L/day